Andrew ElBardissi, MD
Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.
Dr. ElBardissi’s board memberships include Acutus, Farapulse, SentreHeart, Sollis Therapeutics, vWave, Conventus, Neochord, Incarda Therapeutics, Epic Sciences, and Cathworks.